InvestorTalk Alert: Andre Larente from Diagnos Inc. to host on Thursday, September 5, 2024

InvestorNews is pleased to announce an upcoming InvestorTalk scheduled for tomorrow, Thursday, September 5th, at 9 AM EST, featuring Andre Larente, President, CEO, and Director of Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF). To participate in this engaging discussion, please click here

Currently, DIAGNOS holds 76,766,767 shares outstanding and has a market capitalization of CAD$30,322,873.

In preparation for tomorrow’s InvestorTalk, here are the four most recent news releases from DIAGNOS for your review, which are listed below:

• August 22, 2024 – DIAGNOS Announces Date of Annual General and Special Meeting of Shareholders — click here
• August 20, 2024 — DIAGNOS Successfully Completes ISO 13485 / MDSAP Audit and receives its certification to move forward with FDA and Health Canada — click here
• June 05, 2024 — DIAGNOS Announces Closing of Second and Final Tranche of Private Placement — click here
• May 21, 2024 — DIAGNOS celebrates the launch of Labtician’s new screening service for diabetic retinopathy in Ontario and renews its distribution agreement — click here

5-Data Points from DIAGNOS’ news release titled, DIAGNOS Successfully Completes ISO 13485 / MDSAP Audit and receives its certification to move forward with FDA and Health Canada:

1. ISO 13485 / MDSAP Certification: DIAGNOS has successfully completed its ISO 13485 audit and received certification, allowing the company to move forward with FDA and Health Canada.
2. Medical Device Single Audit Program (MDSAP): The certification is crucial for the commercialization of DIAGNOS’ flagship product, CARA, which focuses on early detection of health issues through AI and retinal imaging.
3. Global AI Healthcare Market Growth: The global AI healthcare market is projected to grow from USD $19.27 billion in 2023 to USD $613.81 billion by 2034, with a CAGR of 36.83% between 2024-2034.
4. Regulatory Approvals: DIAGNOS is obtaining regulatory licenses in Canada (Health Canada) and the USA (FDA) for four new modules aimed at detecting retinal conditions, including Age-Related Macular Degeneration and Diabetic Retinopathy.
5. Expanding Product Suite: DIAGNOS has evolved from offering a single diabetic test to a broader suite of diagnostic tools, accelerating both profitability and patient satisfaction.

(09.04.2024 at 6:00 AM EST, Source)

For more information on Diagnos Inc., click here

For more information on the InvestorTalk pre-market series, go to InvestorTalk.com.